AbbVie Inc. (ABBV)
AbbVie's Post-Humira Strategy Is Paying Off For Investors
AbbVie offers a compelling blend of high yield, consistent dividend growth, and strong financials, making it attractive for income-focused investors. The company has successfully transitioned from Humira, with Rinvoq and Skyrizi driving impressive revenue growth and offsetting patent expirations. AbbVie's robust pipeline and strategic acquisitions position it for continued growth, supporting ongoing dividend increases and shareholder returns.
AbbVie Inc. (ABBV) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
AbbVie Inc. (NYSE:ABBV ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Company Participants Jeffrey Ryan Stewart - Executive VP & Chief Commercial Officer Robert A. Michael - CEO & Director Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer Scott T.
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
The latest trading day saw AbbVie (ABBV) settling at $187.66, representing a +0.17% change from its previous close.
Bert's May 2025 Dividend Income Summary
Our dividend income dropped by 15% in May. We had Healthpeak Properties change the structure of its dividend. June will be a very exciting month and I cannot wait to see the dividend distributions for our ETFs, especially SCHD.
AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip?
ABBV drops 12.6% in three months, but rising Skyrizi and Rinvoq sales, pipeline strength, and 2025 growth outlook support staying invested.
When $7 Trillion Wakes Up: Buy These 3 Dividend Stocks Before Everyone Else Does
Money market funds are booming with $7.2 trillion in assets, offering attractive short-term yields, but rising fees and competition could shake things up. I believe we're nearing a turning point: lower rates may push massive capital into dividend stocks, boosting prices and driving down future yields. In the second half of the article, I highlight three high-quality dividend stocks I believe could significantly benefit from this money market rotation trend.
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Best Dividend Aristocrats For June 2025
Dividend Aristocrats have slightly outperformed the S&P 500 year-to-date, despite underperforming in April and May. Dividend growth remains robust, with 41 of 69 Aristocrats announcing increases in 2025 and the average growth rate at 4.75%. 22 Aristocrats appear both undervalued and offer a projected long-term annualized return of at least 10%, based on dividend yield theory and earnings growth.
The Only 5 ETFs You Need to Build Wealth for Retirement
Dividend stocks are a foundational building block for creating a retirement portfolio, offering a reliable income stream and potential for capital appreciation.
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.
Dividend stocks can be a smart way to generate steady income, especially in uncertain markets. However, not all dividend payers are created equal.
